PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2016 | 6 | 1 | A27-28
Article title

Ongoing research developments in cardio-oncology

Content
Title variants
Languages of publication
EN
Abstracts
Keywords
Discipline
Publisher

Journal
Year
Volume
6
Issue
1
Pages
A27-28
Physical description
Contributors
author
  • The Ottawa Hospital Cancer Centre, University of Ottawa, Ontario, Canada, sdent@toh.ca
author
  • The Ottawa Hospital Cancer Centre, University of Ottawa, Ontario, Canada
  • Vanderbilt University, Division of Cardiology, United States
References
  • 1. Amiri-Kordestani L, Beaver JA, Cortazar P. Neoadjuvant Therapy As a Platform for Drug Development: Current Controversies and Regulatory Perspectives. Oncology (Williston Park) 2015; 29(11): 843-844, 846.
  • 2. Amiri-Kordestani L, Wedam S, Zhang L et al. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 2014; 20(21): 5359-5364.
  • 3. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice. Fed Requist 2010; 75(44): 10487-10488.
  • 4. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013; 63(4): 249-279.
  • 5. Herndon TM, Deisseroth A, Kaminskas E et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19(17): 4559-4563.
  • 6. Sysa-Shah P, Tocchetti CG, Gupta M et al. Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. Cardiovasc Res 2015; Dec 21. pii: cvv274 [epub ahead of print].
Document Type
minireview
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-d19cf357-a7dd-4329-b046-1831289b9b23
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.